Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA

https://doi.org/10.17749/2070-4909.2015.8.2.043-054

Full Text:

Abstract

The purpose of the work performed was assessment of cost efficiency of Raltegravir within the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group of protease inhibitors with adult patients with Type 1 HIV infection (HIV-1) that have no experience of treatment.

Materials and methods. In the Markov's model developed for assessment of long-term clinical and economic indicators of efficiency of Raltegravir with adult patients with HIV-1 that have no experience of antiretroviral therapy, pharmacoeconomic analysis of "costs and benefits" was performed in accordance with recommendations of the Panel on Cost-effectiveness in Health and Medicine and with consideration of requirements of specialized Russian manuals. Direct costs for application of the schemes compared were calculated on the basis of applicable norms of financing of the Russian Federation. Consumptions of health care resources and life standard indicators were determined on the basis of foreign studies regarding each of the 18 states of health provided with Markov's model and distinguished according to the number of CD4 cells and viral load.

Study results. It was demonstrated that Raltegravir within schemes of antiretroviral therapy of the first line, as compared to the schemes on the basis of drugs from the group of protease inhibitors with subsequent second line therapy on the basis of non-nucleoside reverse transcriptase inhibitors (including Raltegravir in addition to the optimized treatment at the last stage), was a more cost efficient alternative as it had clinical benefits with affordable additional expenses. The increment cost efficiency rate (ICER) per a year of saved life with consideration of its quality comprised 1,097,078 rubles without exceeding the threshold of readiness to pay for a year of quality life equal to 3 GDP per capita.

About the Authors

Elamin H. Elbasha
Health Economic Statistics of Merck Research Laboratories
United States

PhD, 

P.O. Box 1000, North Wales, Pennsylvania, United States, 19454



Elena Aleksandrovna Pyadushkina
Institute of Russian academy of national economy and public administration; Autonomous Non-profit Organization “National Center for Health Technology Assessment”; RANEPA IPEI, Laboratory for health technology assessment
Russian Federation

research fellow of Laboratory for health technology assessment of Applied economic research;

research fellow, Vernadskogo prospect, 82-1, Moscow, 119571



Maria Vladimirovna Avxentyeva
Institute of Russian academy of national economy and public administration; First Moscow state medical university named after I.M. Sechenov; RANEPA IPEI, Laboratory for health technology assessment
Russian Federation

PHD (doctor of medical sciences), leading research fellow of Laboratory for health technology assessment of Applied economic research;

leading research fellow of Centre for health finance of Research Financial institution of Ministry of Finance and professor of High school of healthcare management, Vernadskogo prospect, 82-1, Moscow, 119571



Alexander Gennadievich Tolkushin
MSD Pharmaceuticals
Russian Federation

PHD (candidate of pharmaceutical sciences), leading specialist,

Pavlovskaya ulitsa, 7 build 1, Moscow, 115093



Maxim Yurievich Frolov
Volgograd state medical university
Russian Federation

PHD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department,

Pavshih borzov pl., 1, Volgograd, 400131



References

1. World Health Organization [Vsemirnaya organizatsiya zdravookhraneniya (in Russian)]. URL: http://www.who.int/hiv/data/en/ (accessed 10.04.2015).

2. Information letter from the Russian Ministry of Public Health of 22.12.2011 № 20-2 / 10 / 1-8234 "On the formation and economic feasibility of the territorial program of state guarantees of the Russian Federation citizens free medical care in 2012." [Informatsionnoe pis'mo Minzdravsotsrazvitiya Rossii ot 22.12.2011 g. № 20-2/10/1-8234 «O formirovanii i ekonomicheskom obosnovanii territorial'noi programmy gosudarstvennykh garantii okazaniya grazhdanam Rossiiskoi Federatsii besplatnoi meditsinskoi pomoshchi na 2012 god» (in Russian)].

3. Clinical and economic analysis (assessment, selection of medical technology and quality management of medical care). Ed. PA Vorobyov. Moscow [Kliniko-ekonomicheskii analiz (otsenka, vybor meditsinskikh tekhnologii i upravlenie kachestvom meditsinskoi pomoshchi). Pod red. P.A. Vorob'eva. Moscow (in Russian)]. 2008; 778 s.

4. R & D "HIV and AIDS in Russia – assessment of the socio-economic loss of society, the effectiveness of drug therapy, improvement of the institutional framework for combating this infection" of the National Research University "Higher School of Economics", 2013 [NIR «VICh-infektsiya i SPID v Rossii – otsenka sotsial'no-ekonomicheskikh poter' obshchestva, effektivnost' medikamentoznoi terapii, sovershenstvovanie institutsional'noi bazy bor'by s etoi infektsiei» Natsional'nogo issledovatel'skogo universiteta «Vysshaya shkola ekonomiki», 2013. (in Russian)]. URL: http://arvt.ru/publications/clinical-researches/HIVAIDS-Russia.html (accessed 10.05.2014).

5. Letter from the Ministry of Health on 20 December 2012 № 14-6 / 10 / 2-5305 (rev. On 11.11.2013) On the direction of the recommendations "Payment of medical care under the program of state guarantees on the basis of groups of diseases, including clinical and statistical groups of diseases (DRG) [Pis'mo Ministerstva zdravookhraneniya RF ot 20 dekabrya 2012 g. № 14-6/10/2-5305 (s izm. ot 11.11.2013) O napravlenii rekomendatsii “Sposoby oplaty meditsinskoi pomoshchi v ramkakh programmy gosudarstvennykh garantii na osnove grupp zabolevanii, v tom chisle kliniko-statisticheskikh grupp boleznei (KSG)” (in Russian)] URL: http://www.garant.ru/products/ipo/prime/doc/70207014/ (accessed 08.04.2015).

6. Pokrovskii V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanestri V.G., Shakhgil'dyan V.I., Buravtsova E.V., Kozyrina N.V., Narsiya R.S., Pokrovskaya A.V., Efremova O.S., Konnov V.V., Konnov D.S., Kuimova U.A., Popova A.A., Khokhlova O.N., Voronin E.E., Afonina L.Yu., Vasil'eva I.A., Zimina V.N. National recommendations for dispensary observation and treatment of patients with HIV infection (the project) [Natsional'nye rekomendatsii po dispansernomu nablyudeniyu i lecheniyu bol'nykh VICh-infektsiei (proekt) (in Russian)] URL: http://www.hivrussia.org/files/Nac_recom2015.pdf (accessed 08.04.2015).

7. Pokrovskii V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Kanestri V.G., Afonina L.Yu. et al. Epidemiol. infekts. bolezni. Aktual. vopr. 2013; 6: 1-31.

8. Pokrovskii V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Kanestri V.G., Afonina L.Yu., Ermak T.N., Buravtsova E.V., Shakhgil'dyan V.I., Kozyrina N.V., Narsiya R.S., Zimina V.N., Pokrovskaya A.V., Efremova O.S. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy. 2014; 6: 2-43.

9. Resolution of the Government of Moscow on December 24, 2013 N 892-PP of the territorial program of state guarantees of free provision of medical care to citizens in Moscow in 2014 and the planned period 2015 and 2016 [Postanovlenie Pravitel'stva Moskvy ot 24 dekabrya 2013 g. N 892-PP O Territorial'noi programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi v gorode Moskve na 2014 god i na planovyi period 2015 i 2016 godov (in Russian)].

10. Resolution of the Government of Moscow dated 24.02.2010 N 163-PP (ed. By 22.09.2011) "On establishing size limits trade allowances to the prices of medicines" [Postanovlenie Pravitel'stva Moskvy ot 24.02.2010 N 163-PP (red. ot 22.09.2011) "Ob ustanovlenii predel'nykh razmerov torgovykh nadbavok k tsenam na lekarstvennye sredstva" (in Russian)].

11. Resolution of the Government of the Russian Federation dated October 18, 2013 N 932 Moscow "On the program of state guarantees of free provision of medical care to citizens in 2014 and the planned period 2015 and 2016" [Postanovlenie Pravitel'stva Rossiiskoi Federatsii ot 18 oktyabrya 2013 g. N 932 g. Moskva "O programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2014 god i na planovyi period 2015 i 2016 godov" (in Russian)].

12. Order of the Russian Ministry of Health from 09.11.2012 N 758n "On approval of the standard of specialized medical care for diseases caused by the human immunodeficiency virus (HIV)" (Registered in the Ministry of Justice of Russia 18.01.2013 N 26599) [Prikaz Minzdrava Rossii ot 09.11.2012 N 758n "Ob utverzhdenii standarta spetsializirovannoi meditsinskoi pomoshchi pri bolezni, vyzvannoi virusom immunodefitsita cheloveka (VICh-infektsii)" (Zaregistrirovano v Minyuste Rossii 18.01.2013 N 26599) (in Russian)].

13. Rossiya`2015 articles. Directory / P76 Rosstat. M. 2015; 62 c. [Rossiya`2015: Stat. Spravochnik /R76 Rosstat. M. 2015; 62 s. (in Russian)] URL: http://www.gks.ru/free_doc/doc_2015/rus15.pdf (accessed 10.04. 2015).

14. Federal Scientific and Methodological Centre for the Prevention and Control of AIDS [Federal'nyi nauchno-metodicheskii tsentr po profilaktike i bor'be so SPIDom (in Russian)]. URL: http://www.hivrussia.org/files/bul_38.pdf. (accessed 10.05.2015).

15. British Columbia Center for Excellence in HIV/AIDS. URL: http://www.cfenet.ubc.ca/ 2007 (accessed 06.10.2008).

16. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report 2003; 15: 40. URL: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2003report/pdf/2003SurveillanceReport.pdf (accessed 06.10.2008).

17. Chaudhary M.A., Moreno S., Kumar R.N., Nocea G., Elbasha E. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. AIDS Res Hum Retroviruses. 2009 Jul; 25 (7): 679-89.

18. Chaudhary M.A., Elbasha E.H., Kumar R.N., Nathanson E.C. Cost-effectiveness of raltegravir in HIV/AIDS. Expert Rev Pharmacoecon Outcomes Res. 2011 Dec; 11 (6): 627-39.

19. DeJesus E., Rockstroh J., Lennox J., Saag M., Lazzarin A., Wan H. et al. Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRKm, Infectious Diseases Society of America (IDSA) 49th Annual Meeting, October 20-23, Boston MA (Abstract 30623, Poster H.405). 2011.

20. Elbasha E., Szucs T., Chaudhary M., Kumar R., Roediger A., Cook H. et al. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clinical Trials. 2009 July-Aug 2009; 10 (4): 233-53.

21. Eron J., Cooper D., Steigbigel R., Clotet B., Wan H., Zhao J. et al. Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory, Analysis of Late Outcomes Based on Early Virologic Response XIX International AIDS Conference, July 22-27, 2012, Washington, DC (Abstract# A-452-0098-12576). 2012.

22. European AIDS Clinical Society (EACS) Guidelines for treatment of HIV-infected adults in Europe. Version 7.01 – November 2013. URL: http://www.eacsociety.org/Guidelines.aspx. http://www.eacsociety.org/Portals/0/GUIDELINES/EACS_7.01%20RU.pdf (accessed 07.04.2015).

23. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007 Apr 14; 369 (9569): 1261-9.

24. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. URL: (http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Downloaded from http://aidsinfo.nih.gov/guidelines on 10/29/2014).

25. ISPOR 2006 Guidelines on Health Economic Evaluations. URL: http://www.ispor.org/PEguidelines/index.asp (accessed 01.04.2015).

26. ISPOR 2006 Guidelines on Health Economic Evaluations: Protocol on the Procedure for Clinical and Economic Evaluation of Drugs which are submitted for inclusion into reimbursed drug lists, Moscow (2010). URL: http://www.ispor.org/peguidelines/index.asp (accessed 20.05.2015).

27. Lennox J., DeJesus J., al ELe. Raltegravir Demonstrates Durable Efficacy through 96 Weeks (Wk): Results from STARTMRK, A Phase III Study of Raltegravir (RAL)-based vs Efavirenz (EFV)-based Therapy in Treatment-Naive HIV+ Patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009 (Abstract H-924b). San Francisco. 2009.

28. Lennox J., DeJesus J., al. ELe. STARTMRK. A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-Infected Patients. ICAAC-IDSA 2008. Washington, DC October 25-28, 2008 (Abstract H-896a). 2008.

29. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V.R., Berger D.S. et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet. 2009; 374 (9692): 796-806.

30. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002 Aug 8; 347 (6): 385-94.

31. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P. et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001 Jul 3; 135 (1): 17-26.

32. Nelson M., Dockrell D.H., Edwards S. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011 //HIV medicine. 2011. URL: http://www.bhiva.org/documents/guidelines/oi/hiv_v12_is2_iss2press_text.pdf (accessed 20.12.2007).

33. Simpson K.N., Luo M.P., Chumney E., Sun E., Brun S., Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the firstline highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004 Sep-Oct; 5 (5): 294-304.

34. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M. et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24; 359 (4): 339-54.


For citation:


Elbasha E.H., Pyadushkina E.A., Avxentyeva M.V., Tolkushin A.G., Frolov M.Y. ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(2):43-54. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.2.043-054

Views: 634


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)